IGC Pharma Inc (IGC) Q2 2025 Earnings Report

IGC reported Q2 2025 revenue of $412 thousand, marking a YoY increase of 41.58% and a QoQ advance of 51.47% driven by modest top-line growth across its two segments. Despite the revenue uptick and a gross margin of 48.06%, the quarter delivered a sizable operating loss of $1.76 million and a net loss of $1.72 million, translating to an EPS of -0.0226. The margin compression is largely a function of steep operating spend, notably R&D at $0.917 million and SG&A at $1.041 million, which overwhelmed the incremental gross profit from sales.

Cash flow remained negative on an operating basis, with operating cash flow of -$0.996 million and free cash flow of -$0.932 million. Financing activities provided a modest liquidity cushion of $0.794 million, but overall the company exhausted cash by $0.278 million during the period, ending with cash and equivalents of $1.546 million. The balance sheet shows a solid equity base of approximately $7.378 million against modest leverage (total debt $0.304 million; net debt negative $1.242 million due to cash holdings).

With a small revenue base and ongoing losses, the near-term investment thesis hinges on meaningful top-line scaling and sustained cost discipline. IGC’s diversified exposure to infrastructure equipment rental and cannabidiol-based life sciences products provides optionality, but there is no formal forward guidance disclosed in the QQ2 2025 filing. Investors should monitor (i) the trajectory of revenue growth to achieve operating leverage, (ii) the company’s ability to manage working capital and reduce SG&A as a percentage of revenue, (iii) potential strategic actions or partnerships to monetize non-core assets, and (iv) regulatory developments affecting the cannabinoid business and potential contract wins in infrastructure segments.